This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Treosulfan
DrugBank Accession Number
DB11678
Background

Treosulfan is under investigation in Allogeneic Haematopoietic Stem Cell Transplantation. Treosulfan has been investigated for the treatment of Lymphoblastic Leukemia, Acute, Childhood.

Type
Small Molecule
Groups
Approved, Investigational
Structure
Weight
Average: 278.29
Monoisotopic: 278.013009759
Chemical Formula
C6H14O8S2
Synonyms
  • DIHYDROXYBUSULFAN
  • OVASTAT
  • Treosulfan
External IDs
  • NSC-39069

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Treosulfan.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Treosulfan.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Treosulfan.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Treosulfan.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TrecondiInjection, powder, for solution5 gIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2020-12-16Not applicableEU flag
TrecondiInjection, powder, for solution1 gIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2020-12-16Not applicableEU flag
TrecondiInjection, powder, for solution5 gIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2020-12-16Not applicableEU flag
TrecondiInjection, powder, for solution1 gIntravenousMedac Gesellschaft Für Klinische Spezialpräparate Mb H2020-12-16Not applicableEU flag
TrecondyvPowder5 g / vialIntravenousMedexus Inc2021-08-31Not applicableCanada flag
TrecondyvPowder1 g / vialIntravenousMedexus IncNot applicableNot applicableCanada flag

Categories

ATC Codes
L01AB02 — Treosulfan
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as organosulfonic acid esters. These are esters of sulfonic acid, which have the general structure RS(=O)2OR' (R,R' = organyl, not H).
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic sulfonic acids and derivatives
Sub Class
Organosulfonic acids and derivatives
Direct Parent
Organosulfonic acid esters
Alternative Parents
Sulfonic acid esters / Sulfonyls / Methanesulfonates / Secondary alcohols / 1,2-diols / Organic oxides / Hydrocarbon derivatives
Substituents
1,2-diol / Alcohol / Aliphatic acyclic compound / Hydrocarbon derivative / Methanesulfonate / Organic oxide / Organic oxygen compound / Organooxygen compound / Organosulfonic acid ester / Organosulfur compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
methanesulfonate ester (CHEBI:82557)
Affected organisms
Not Available

Chemical Identifiers

UNII
CO61ER3EPI
CAS number
299-75-2
InChI Key
YCPOZVAOBBQLRI-WDSKDSINSA-N
InChI
InChI=1S/C6H14O8S2/c1-15(9,10)13-3-5(7)6(8)4-14-16(2,11)12/h5-8H,3-4H2,1-2H3/t5-,6-/m0/s1
IUPAC Name
(2S,3S)-2,3-dihydroxy-4-(methanesulfonyloxy)butyl methanesulfonate
SMILES
CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O

References

General References
  1. EMA Summary of Product Characteristics: Trecondi (treosulfan) powder for solution for infusion [Link]
KEGG Compound
C19557
PubChem Compound
9882105
PubChem Substance
347828046
ChemSpider
8057780
RxNav
38508
ChEBI
82557
ChEMBL
CHEMBL455186
ZINC
ZINC000001671094
Wikipedia
Treosulfan

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
3CompletedTreatmentEwing's Sarcoma1
3CompletedTreatmentOvarian Cancer1
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute, Childhood2
3Unknown StatusTreatmentMelanoma1
2Active Not RecruitingTreatmentAcute myeloid leukaemia (in remission) / Chronic Myelomonocytic Leukemia (CMML) / Minimal Residual Disease / Myelodysplastic Syndromes (MDS) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Myelodysplastic/Myeloproliferative Neoplasms1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS) / Transplant-Related Hematologic Malignancy1
2Active Not RecruitingTreatmentBone Marrow Failure Syndromes / Haemoglobinopathies congenital / Inborn Errors of Metabolism / Primary Immunodeficiencies (PID)1
2CompletedSupportive CareAcute Myeloid Leukemia (AML)1
2CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia (CML) / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Chronic Myelogenous Leukemia, Blastic Phase / Chronic Myelomonocytic Leukemia (CMML) / De Novo Myelodysplastic Syndromes / Myelodysplastic Syndromes, Previously Treated / Recurrent Acute Myeloid Leukemia, Adult / Recurrent Adult Acute Lymphoblastic Leukemia (ALL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Injection, powder, for solutionIntravenous1 G
Injection, powder, for solutionIntravenous5 G
PowderIntravenous1 g / vial
PowderIntravenous5 g / vial
Powder, for solution
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility17.0 mg/mLALOGPS
logP-1.5ALOGPS
logP-2.6ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)12.99ChemAxon
pKa (Strongest Basic)-3.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area127.2 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity51.98 m3·mol-1ChemAxon
Polarizability24.93 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at October 20, 2016 20:39 / Updated at June 27, 2022 14:55